- Home
- YGMZ vs PBM Comparison
YGMZ vs PBM Comparison
Compare YGMZ & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- PBM
- Stock Information
- Founded
- YGMZ 2002
- PBM 1994
- Country
- YGMZ China
- PBM Canada
- Employees
- YGMZ N/A
- PBM N/A
- Industry
- YGMZ Transportation Services
- PBM
- Sector
- YGMZ Consumer Discretionary
- PBM
- Exchange
- YGMZ Nasdaq
- PBM NYSE
- Market Cap
- YGMZ 7.0M
- PBM 7.5M
- IPO Year
- YGMZ 2020
- PBM N/A
- Fundamental
- Price
- YGMZ $0.86
- PBM $1.79
- Analyst Decision
- YGMZ
- PBM
- Analyst Count
- YGMZ 0
- PBM 0
- Target Price
- YGMZ N/A
- PBM N/A
- AVG Volume (30 Days)
- YGMZ 124.8K
- PBM 5.4M
- Earning Date
- YGMZ 01-01-0001
- PBM 02-02-2025
- Dividend Yield
- YGMZ N/A
- PBM N/A
- EPS Growth
- YGMZ N/A
- PBM N/A
- EPS
- YGMZ N/A
- PBM N/A
- Revenue
- YGMZ $55,805,416.00
- PBM N/A
- Revenue This Year
- YGMZ N/A
- PBM N/A
- Revenue Next Year
- YGMZ N/A
- PBM N/A
- P/E Ratio
- YGMZ N/A
- PBM N/A
- Revenue Growth
- YGMZ N/A
- PBM N/A
- 52 Week Low
- YGMZ $0.68
- PBM $1.51
- 52 Week High
- YGMZ $6.24
- PBM $593.25
- Technical
- Relative Strength Index (RSI)
- YGMZ 44.05
- PBM 39.22
- Support Level
- YGMZ $0.68
- PBM $1.61
- Resistance Level
- YGMZ $0.85
- PBM $2.25
- Average True Range (ATR)
- YGMZ 0.09
- PBM 0.22
- MACD
- YGMZ -0.01
- PBM 0.06
- Stochastic Oscillator
- YGMZ 40.23
- PBM 23.38
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.